FiberCop selects Adtran to support high-speed metro transport network across Italy
20.1.2026 14:00:00 CET | Business Wire | Press release
News summary: Leading wholesale network operator needed a scalable, space-efficient metro solution to support its national open-access strategy Adtran’s FSP 3000 open optical technology and Mosaic Network Controller chosen to deliver flexible, high-capacity transport Coherent 100ZR pluggable optics will enable cost- and power-efficient 100G metro links across major Italian cities
Adtran today announced that it has been selected by FiberCop, Italy’s leading wholesale-only fiber operator, as one of the technology partners to provide optical transport for a nationwide metro rollout. Built to support high-capacity open-access connectivity, the network will bring enhanced scalability and flexibility to Italy’s digital infrastructure. FiberCop selected Adtran for its open optical transport technology, Mosaic Network Controller management software and coherent 100ZR pluggable optics, which deliver compact, economical and power-efficient 100Gbit/s connectivity across metro locations. The decision also reflects more than 20 years of trusted collaboration and a shared commitment to building open networking platforms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120094193/en/
Adtran’s technology is helping FiberCop roll out a national open-access network.
“This metro transport rollout is a critical part of FiberCop’s strategy to deliver open-access connectivity at scale across the country,” said Christoph Glingener, CTO of Adtran. “Our technology provides the performance, space efficiency and automation capabilities FiberCop needs to accelerate deployment and streamline operations. The close working relationship between our teams has contributed to many of our most successful projects in recent years. This strong foundation will enable FiberCop to scale more quickly and seamlessly integrate new services, partners and platforms as they continue to expand and modernize their network.”
The new network will be built using Adtran’s FSP 3000 open optical transport platform, including AccessFlex™ and M-Flex800™ terminals supporting a range of metro node configurations. It will leverage open line system solutions optimized for specific network requirements: FSP 3000 Core OLS for ROADM-based transport and Edge OLS for flexible aggregation at the edge. This enables 100Gbit/s and 400Gbit/s DWDM connectivity, delivering the scalability and efficiency needed for FiberCop’s evolving service model. Compact coherent 100ZR pluggables will also be deployed to enable high-density 100Gbit/s metro links with lower space and power demands. What’s more, centralized management and control will be provided by Adtran’s Mosaic Network Controller, paving the way for seamless automation.
“This deployment showcases the power of our open optical and software platforms to meet national-scale challenges,” commented Stuart Broome, GM of EMEA and APAC sales at Adtran. “FiberCop required a solution combining high capacity with space and power efficiency, while also supporting automation and future growth. With our FSP 3000 platform, 100ZR pluggables and Mosaic Network Controller, we’re enabling a flexible transport network that’s ready to scale with demand. This project highlights the close working relationship between our teams and our shared commitment to accelerating open-access connectivity across Italy.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260120094193/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom